US Biosimilars Market – 5 Things to Look Out for in 2022

The biosimilars market in the US has ramped up significantly in the past year, amidst rising political pressure surrounding high drug prices. This growth comes in spite of efforts from manufacturers to block the approval of biosimilars for key blockbuster drugs like Humira. In a new PharmaPhorum article, Elizabeth McMahon, senior VP of emerging therapies and channel strategy at AmerisourceBergen, shares 5 events and trends to watch this year.

According to McMahon, “As more biosimilars launch, I continue to observe how manufacturers of innovator products respond to these entrants. For example, Janssen released an unbranded version of Remicade to push back on three biosimilars in the infliximab space. The unbranded version, which is identical to the brand-name product, specifically targets Part B and not commercial plans. So, it will be interesting to watch how this continues to play out.”

To read more, click here.

(Source: PharmaPhorum, April 1^st, 2022)